VASOHIBIN: POTENTIAL TARGETING INHIBITOR OF ANGIOGENESIS IN COLORECTAL CANCER

• Grant number: 18/21471-5
• Support Opportunities: Regular Research Grants
• Start date: June 01, 2019
• End date: November 30, 2021
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Denise Gonçalves Priolli
• Grantee: Denise Gonçalves Priolli
• Host Institution: Universidade São Francisco (USF). Campus Bragança Paulista. Bragança Paulista , SP, Brazil
• Associated research grant(s): 19/23592-7 - Vasohibin aptamer (VASH-aptamer): a potential theranostic agent in colorectal cancer, AP.R SPRINT

Abstract

Angiogenesis is a term that describes the blood vessels formation, a physiological process involved in growth and healing, which is also linked to the development of diseases, including cancer in its progression and metastasis development. Differently, tumor angiogenesis is characterized by the neovessels formation from of the endothelial proliferation of preexisting vessels stimulation and, thus is called neoangiogenesis. Among the most recently described angiogenesis regulators are vasohibins (VASHs). The vasohibin family is composed of two members, vasohibin-1 (VASH-1), which is expressed in vessels and in colorectal cancer and is prognostic-related, and vasohibin-2 (VASH-2), its homologue, which is expressed in the tumor tissue and appears as stimulatory action on angiogenesis. Currently, the antiangiogenic therapy is an option, especially in cancer advanced stages, but their side effects are still vast, due to their action on targets in tumor endothelium and in normal endothelium. In addition, the drug resistance development has been a problem in antiangiogenic drugs. The specific target identification, such as VASH, arouses interest in antiangiogenic therapy, however its role must be better understood in colorectal cancer. This project is divided into two distinct phases. In Phase I, it is intended to understand the VASH (1 and 2) behavior in colorectal cancer (CCR) carcinogenesis from biopsies of normal tissue samples, adenoma and adenocarcinoma, while in phase II a new antiangiogenic agent is searched in animal model of human colon cancer. For this, morphological methods, immunohistochemical, xenotransplantation techniques, cell culture, recombineants will be used. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

MACKSON MARTINS ROCHA; ISABELA DARIVA; GABRIELA COMELLI ZORNOFF; GIOVANNA SANCHES DE LAURENTIS; GIULIA CARLI MENDES; MAYCON GIOVANI SANTANA; GUILHERME CHOHFI DE MIGUEL; RUI SEABRA FERREIRA JUNIOR; JULIANA MOZER SCIANI; DENISE GONÇALVES PRIOLLI. A new therapeutic approach for bone metastasis in colorectal cancer: intratumoral melittin. Journal of Venomous Animals and Toxins including Tropical Diseases, v. 28, 2022-03-14. (18/21471-5)

PELOSI, ANDREA; FERNANDES, ANNA MARIA A. P. C.; MACIEL, LEONARDO; SILVA, ALEX A. R.; MENDES, GIULIA F.; BUENO, LUISA F. G.; SILVA, LIVIA MARIA F. M.; BREDARIOL, RAFAEL G.; SANTANA, MAYCON; PORCARI, ANDREIA; et al. Liquid chromatography coupled to high-resolution mass spectrometry metabolomics: A useful tool for investigating tumor secretome based on a three-dimensional co-culture model. PLoS One, v. 17, n. 9, p. 8-pg., 2022-09-21. (19/04314-6, 18/21471-5, 19/23592-7, 18/21906-1)

KRAEMER, MAURICIO BEITIA; SILVA, KAREN CHRISTINE; KRAEMER, CAMILA CUNHA FRANCA; PEREIRA, JULIANA SILVA; DOS REIS, IVAN GUSTAVO MASSELI; PRIOLLI, DENISE GONCALVES; MESSIAS, LEONARDO HENRIQUE DALCHECO. Validity of the peak velocity to detect physical training improvements in athymic mice. FRONTIERS IN PHYSIOLOGY, v. 13, p. 11-pg., 2022-08-24. (19/23592-7, 18/21471-5)